IRVINE, CA., May 4, 2012 /PRNewswire/ — Andrew Technologies, LLC introduced the HydraSolve™ Liposuction System today at the American Society for Aesthetic Plastic Surgery (ASAPS) in Vancouver, BC. ASAPS is the premier plastic surgery medical conference for surgeons focused on aesthetic body contouring and is attended by approximately 3,000 plastic surgeons.
HydraSolve™ is an FDA-cleared liposuction device based on the same patented Tissue Liquefaction Technology™ launched in 2003 by Alcon as the AquaLase® Liquefaction Device for precision cataract surgery. HydraSolve™ combines natural saline solution with low levels of pressure and temperature to liquefy only the targeted fatty tissue. Because the adipose tissue is liquefied, it is no longer necessary to cut the fat with strong thrusts of the cannula. The specially designed HydraSolve™ cannula is manufactured with opening tips that have a rounded radius of curvature that does not cut tissue. It is the activated saline stream, inside the cannula, that liquefies the targeted fatty tissue while not damaging or cutting blood vessels, nerves or connective tissue. HydraSolve™ achieves fat tissue liquefaction by cell disruption, not cell membrane lysis.
The HydraSolve™ system is on display at booth #333. There is also a Hot Topics presentation today by Dr. Richard D’Amico (past ASPS President) where Dr. D’Amico will highlight his clinical experiences with HydraSolve. In addition, Andrew Technologies has submitted two e-Posters. Scientific Poster # 5266 provides data from safety studies supporting FDA approval, Scientific Poster # 5233 provides the results of the largest consumer survey ever reported on Liposuction with 21,509 respondents.
Since FDA clearance of HydraSolve™ in 2010, Andrew Technologies has engaged in clinical development of the device with several leading Plastic Surgeons to demonstrate the full potential of HydraSolve in more than 50 patient cases. According to Dr. Richard D’Amico of Englewood, NJ, “It is clearly more effective and my opinion is that it is less traumatic and may result in less blood loss for a given amount of liposuction.” Dr. Christopher Godek of Toms River, NJ, and President of the NJ Society of Plastic Surgery, has contributed to the development of the HydraSolve™ technology since its inception and notes that “HydraSolve™ provides faster, smoother fat extraction for the surgeon, with faster recovery for patients.” Dr. David Abramsonanother plastic surgeon specialist New York and New Jersey started using HydraSolve more recently and added, “With the first patient I saw, at her first post-op visit I had to actively look for any bruising and found almost none.”
Dr. Mark S. Andrew, who co-invented HydraSolve™ and related technologies, is now Chief Scientific Officer of Andrew Technologies and has been directly involved in all HydraSolve™ research and development. According to Dr. Andrew, “HydraSolve™ is better for patients because it’s gentle and tissue-friendly; it’s better for surgeons because it gives them great control and precision in fat removal and also reduces their physical strain.”
About the HydraSolve Lipoplasty System
The HydraSolve™ Lipoplasty System is a pan-American technology. Invented in New Jerseydesigned in Virginia by MPR Associates and manufactured in Ohio and Massachusetts from Spartan Medical http://www.sparton.com/strategic-business-units/medical/ and STD Medical . We expect HydraSolve™ to be very successful in the US launch and in its key export markets Europe, Asiaand South America.
About Andrew Technologies, LLC
Founded in 2007, Andrew Technologies is a medical technology company committed to improving patients’ lives through body aesthetics. Andrew Technologies is a venture capital funded company that will be headquartered in Orange County, CA. Our lead investors are WFD Ventures and the New Jersey Technology Council.
About MPR Associates
MPR is a fully integrated product development, engineering and industrial design company specializing in turnkey product development services in life sciences industries for companies that manufacture medical devices, diagnostics, laboratory instruments and pharmaceuticals. We undertake all aspects of product development, from industrial design, mechanical and electrical design, software development and V&V activities to rapid prototyping of complete systems, manufacturing units for clinical trials and pilot manufacturing and managing technology transfer activities to manufacturers for production full scale.
About Sparton Medical
Sparton Medical’s business consists of contract development, design, manufacturing and fulfillment of complex and sophisticated class I, class II and class III medical devices in its FDA registered and ISO 13485 certified facilities. We ensure reliability and product safety in accordance with Food and Drug Administration (“FDA”) guidelines and GMP manufacturing procedures for each product we design and manufacture. Sparton Medical specializes in systems and processes that meet the requirements of medical OEMs and emerging technology customers in the In Vitro Diagnostic Therapeutic and Surgical Devices market segments.
About STD Med
STD Med is a full service contract manufacturer and developer of precision machined medical devices and components. In business since 1953, this privately held company began its history as Stoughton Tool and Die. Later named STD Manufacturing, the company’s core competency was in machining for the aerospace, defense and commercial industries. In 1990 STDsHis vision changed as he began his transition into the medical device industry. As a result, the company was renamed and STD Med appeared. Housed in multiple facilities totaling over 150 thousand square feet, STD Med is vertically integrated, offering full supply chain management and providing a single point of contact for its customers.
SOURCE Andrew Technologies, LLC
